EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion i
Authors:C Michael Gibson|||Robert P Giugliano|||Robert A Kloner|||Christoph Bode|||Michal Tendera|||András Jánosi|||Bela Merkely|||Jacek Godlewski|||Rim Halaby|||Serge Korjian|||Yazan Daaboul|||Anjan K Chakrabarti|||Kathryn Spielman|||Brandon J Neal|||W Douglas Weaver
Journal: European heart journal
Publication Type: Clinical Trial, Phase II
Date: 2016
DOI: 10.1093/eurheartj/ehv597
ID: 26586786
Affiliations:
Affiliations
PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, RW-459, Boston, MA 02215, USA mgibson@bidmc.harvard.edu.|||Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|||Huntington Medical Research Institutes, Pasadena, CA, USA Cardiovascular Division, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.|||Cardiology and Angiology I, Heart Center, Freiburg University, Freiberg, Germany.|||3rd Department of Cardiology, School of Medicine in Katowice, Medical University of Medicine, Katowice, Poland.|||Gottsegen Gyorgy National Institute of Cardiology, Budapest, Hungary.|||Semmelweis University Heart Center, Budapest, Hungary.|||Krakowski Szpital Specjalistyczny im. Jana Pawla II, Krakow, Poland.|||Harvard Medical School, Boston, MA, USA.|||Harvard Medical School, Boston, MA, USA.|||Harvard Medical School, Boston, MA, USA.|||Eastern Virginia Medical School, Norfolk, VA, USA.|||PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, RW-459, Boston, MA 02215, USA.|||PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, RW-459, Boston, MA 02215, USA.|||Henry Ford Hospital, Detroit, MI, USA.
Abstract
Among patients with ST-elevation myocardial infarction (STEMI), reperfusion injury contributes to additional myocardial damage. MTP-131 is a cell-permeable peptide that preserves the integrity of cardiolipin, enhances mitochondrial energetics, and improves myocyte survival during reperfusion.
